Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Alzheimers Dis ; 43(2): 443-9, 2015.
Article in English | MEDLINE | ID: mdl-25096619

ABSTRACT

BACKGROUND: Patient dependence has rarely been studied in mild-to-moderate Alzheimer's disease (AD). OBJECTIVE: To identify factors which predict patient dependence in mild-to-moderate AD. METHODS: We studied 398 non-institutionalized AD patients (234 females) of the ongoing Prospective Registry on Dementia (PRODEM) in Austria. The Dependence Scale (DS) was used to assess patient dependence. Patient assessment comprised functional abilities, neuropsychiatric symptoms and cognitive functions. A multiple linear regression analysis was performed to identify predictors of patient dependence. RESULTS: AD patients were mildly-to-moderately impaired (mean scores and SDs were: CDR 0.84 ± 0.43; DAD 74.4 ± 23.3, MMSE = 22.5 ± 3.6). Psychopathology and caregiver burden were in the low range (mean NPI score 13.2, range 0 to 98; mean ZBI score 18, range 0-64). Seventy five percent of patients were classified as having a mild level of patient dependence (DS sum score 0 to 6). Patient dependence correlated significantly and positively with age, functional measures, psychopathology and depression, disease duration, and caregiver burden. Significant negative, but low correlations were found between patient dependence, cognitive variables, and global cognition. Activities of daily living, patient age, and disease severity accounted for 63% of variance in patient dependence, whereas cognitive variables accounted for only 11%. CONCLUSION: Dependence in this cohort was mainly related to age and functional impairment, and less so to cognitive and neuropsychiatric variables. This differs from studies investigating patients in more advanced disease stages which found abnormal behavior and impairments of cognition as main predictors of patient dependence.


Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/psychology , Cognition Disorders/etiology , Dependency, Psychological , Disabled Persons , Age Factors , Aged , Aged, 80 and over , Austria , Caregivers/psychology , Cognition Disorders/diagnosis , Cohort Studies , Female , Humans , Linear Models , Male , Middle Aged , Neuropsychological Tests , Predictive Value of Tests , Psychiatric Status Rating Scales , Registries
2.
J Alzheimers Dis ; 35(2): 247-52, 2013.
Article in English | MEDLINE | ID: mdl-23388173

ABSTRACT

BACKGROUND: Few studies have investigated in detail which factors influence activities of daily (ADL) in Alzheimer's disease (AD). OBJECTIVE: To assess the influence of cognitive, gender, and other factors on ADL in patients with mild to moderate AD. METHODS: This study is part of the Prospective Registry on Dementia in Austria (PRODEM) project, a multicenter dementia research project. A cohort of 221 AD patients (130 females; means: age 76 years, disease duration 34.4 months, MMSE 22.3) was included in a cross-sectional analysis. Everyday abilities were assessed with the Disability Assessment for Dementia scale, and cognitive functions with the CERAD plus neuropsychological test battery. Two models of multiple linear regressions were performed to find factors predicting functional decline, one entering demographical and disease related factors, and a joint model combining demographical and disease variables with neuropsychological scores. RESULTS: Non-cognitive factors explained 18%, whereas the adding of neuropsychological variables explained 39% of variance. Poor figural and verbal memory, constructional abilities, old age, longer disease duration, depression, and male gender were independent risk factors for reduced ADL. Instrumental and basic ADL were predicted by similar factors, except gender (predicting only instrumental ADL) and phonological fluency (predictor of basic ADL). CONCLUSION: In addition to demographical factors, disease duration, and depression, neuropsychological variables are valuable predictors of the functional status in AD in an early disease stage.


Subject(s)
Activities of Daily Living/psychology , Alzheimer Disease/psychology , Cognition/physiology , Aged , Aged, 80 and over , Austria , Depression/complications , Depression/psychology , Disability Evaluation , Female , Humans , Longitudinal Studies , Male , Neuropsychological Tests , Psychomotor Performance/physiology , Registries , Regression Analysis , Sex Characteristics , Socioeconomic Factors , Trail Making Test
3.
Neuropsychiatr ; 23(1): 58-63, 2009.
Article in German | MEDLINE | ID: mdl-19272293

ABSTRACT

We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer's disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2--rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination was done at baseline and at week 12 and 24. Skin adherence of the patch was very good or good in 85% of study participants. Only 2.9% of patients had gastrointestinal adverse events. Local skin reactions occurred in 23% of individuals. Skin alteration were mostly mild in severity. In only 6.8% of subjects did they result in termination of treatment. At the earliest skin reactions were observed after 3 months of treatment. Cognitive functioning of patients improved comparable to the controlled trial which led to approval of the rivastigmine patch. In daily routine the safety profile of the rivastigmine patch is favourable, as is the response to treatment. Local, mostly mild skin reactions affect approximately every fifth patient, and they occur relatively late in the course of therapy. Patients and their caregivers should receive detailed information about skin reactions to omit unnecessary drop outs to treatment.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/administration & dosage , Phenylcarbamates/administration & dosage , Administration, Cutaneous , Aged , Aged, 80 and over , Cholinesterase Inhibitors/adverse effects , Female , Follow-Up Studies , Humans , Male , Mental Status Schedule , Phenylcarbamates/adverse effects , Rivastigmine , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...